Skip to main content
Erschienen in: Familial Cancer 3/2011

01.09.2011

A putative Lynch syndrome family carrying MSH2 and MSH6 variants of uncertain significance—functional analysis reveals the pathogenic one

verfasst von: Jukka Kantelinen, Thomas v. O. Hansen, Minttu Kansikas, Lotte Nylandsted Krogh, Mari K. Korhonen, Saara Ollila, Minna Nyström, Anne-Marie Gerdes, Reetta Kariola

Erschienen in: Familial Cancer | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Inherited pathogenic mutations in the mismatch repair (MMR) genes, MSH2, MLH1, MSH6, and PMS2 predispose to Lynch syndrome (LS). However, the finding of a variant or variants of uncertain significance (VUS) in affected family members complicates the risk assessment. Here, we describe a putative LS family carrying VUS in both MSH2 (c.2768T>A, p.Val923Glu) and MSH6 (c.3563G>A, p.Ser1188Asn). Two colorectal cancer (CRC) patients were studied for mutations and identified as carriers of both variants. In spite of a relatively high mean age of cancer onset (59.5 years) in the family, many CRC patients and the tumor pathological data suggested that the missense variation in MSH2, the more common susceptibility gene in LS, would be the predisposing alteration. However, MSH2 VUS was surprisingly found to be MMR proficient in an in vitro MMR assay and a tolerant alteration in silico. By supplying evidence that instead of MSH2 p.Val923Glu the MSH6 p.Ser1188Asn variant is completely MMR-deficient, the present study confirms the previous findings, and suggests that MSH6 (c.3563G>A, p.Ser1188Asn) is the pathogenic mutation in the family. Moreover, our results strongly support the strategy to functionally assess all identified VUS before predictive gene testing and genetic counseling are offered to a family.
Literatur
1.
Zurück zum Zitat Woods MO, Williams P, Careen A et al (2007) A new variant database for mismatch repair genes associated with Lynch syndrome. Hum Mutat 28:669–673PubMedCrossRef Woods MO, Williams P, Careen A et al (2007) A new variant database for mismatch repair genes associated with Lynch syndrome. Hum Mutat 28:669–673PubMedCrossRef
2.
Zurück zum Zitat Hendriks YM, Wagner A, Morreau H et al (2004) Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 127:17–25PubMedCrossRef Hendriks YM, Wagner A, Morreau H et al (2004) Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 127:17–25PubMedCrossRef
3.
Zurück zum Zitat Berends MJ, Wu Y, Sijmons RH et al (2002) Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet 70:26–37PubMedCrossRef Berends MJ, Wu Y, Sijmons RH et al (2002) Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet 70:26–37PubMedCrossRef
4.
Zurück zum Zitat Wagner A, Hendriks Y, Meijers-Heijboer EJ et al (2001) Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree. J Med Genet 38:318–322PubMedCrossRef Wagner A, Hendriks Y, Meijers-Heijboer EJ et al (2001) Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree. J Med Genet 38:318–322PubMedCrossRef
5.
Zurück zum Zitat Wu Y, Berends MJ, Mensink RG et al (1999) Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. Am J Hum Genet 65:1291–1298PubMedCrossRef Wu Y, Berends MJ, Mensink RG et al (1999) Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. Am J Hum Genet 65:1291–1298PubMedCrossRef
6.
Zurück zum Zitat Couch FJ, Rasmussen LJ, Hofstra R et al (2008) Assessment of functional effects of unclassified genetic variants. Hum Mutat 29:1314–1326PubMedCrossRef Couch FJ, Rasmussen LJ, Hofstra R et al (2008) Assessment of functional effects of unclassified genetic variants. Hum Mutat 29:1314–1326PubMedCrossRef
7.
Zurück zum Zitat Ollila S, Sarantaus L, Kariola R et al (2006) Pathogenicity of MSH2 missense mutations is typically associated with impaired repair capability of the mutated protein. Gastroenterology 131:1408–1417PubMedCrossRef Ollila S, Sarantaus L, Kariola R et al (2006) Pathogenicity of MSH2 missense mutations is typically associated with impaired repair capability of the mutated protein. Gastroenterology 131:1408–1417PubMedCrossRef
8.
Zurück zum Zitat Ollila S, Dermadi Bebek D, Jiricny J et al (2008) Mechanisms of pathogenicity in human MSH2 missense mutants. Hum Mutat 29:1355–1363PubMedCrossRef Ollila S, Dermadi Bebek D, Jiricny J et al (2008) Mechanisms of pathogenicity in human MSH2 missense mutants. Hum Mutat 29:1355–1363PubMedCrossRef
9.
Zurück zum Zitat Bisgaard ML, Jager AC, Myrhoj T et al (2002) Hereditary non-polyposis colorectal cancer (HNPCC): phenotype-genotype correlation between patients with and without identified mutation. Hum Mutat 20:20–27PubMedCrossRef Bisgaard ML, Jager AC, Myrhoj T et al (2002) Hereditary non-polyposis colorectal cancer (HNPCC): phenotype-genotype correlation between patients with and without identified mutation. Hum Mutat 20:20–27PubMedCrossRef
10.
Zurück zum Zitat Kantelinen J, Kansikas M, Korhonen MK et al (2010) MutSbeta exceeds MutSalpha in dinucleotide loop repair. Br J Cancer 102:1068–1073PubMedCrossRef Kantelinen J, Kansikas M, Korhonen MK et al (2010) MutSbeta exceeds MutSalpha in dinucleotide loop repair. Br J Cancer 102:1068–1073PubMedCrossRef
11.
Zurück zum Zitat Kariola R, Hampel H, Frankel WL et al (2004) MSH6 missense mutations are often associated with no or low cancer susceptibility. Br J Cancer 91:1287–1292PubMedCrossRef Kariola R, Hampel H, Frankel WL et al (2004) MSH6 missense mutations are often associated with no or low cancer susceptibility. Br J Cancer 91:1287–1292PubMedCrossRef
12.
Zurück zum Zitat de Wind N, Dekker M, Claij N et al (1999) HNPCC-like cancer predisposition in mice through simultaneous loss of Msh3 and Msh6 mismatch-repair protein functions. Nat Genet 23:359–362PubMedCrossRef de Wind N, Dekker M, Claij N et al (1999) HNPCC-like cancer predisposition in mice through simultaneous loss of Msh3 and Msh6 mismatch-repair protein functions. Nat Genet 23:359–362PubMedCrossRef
13.
Zurück zum Zitat Chang DK, Ricciardiello L, Goel A et al (2000) Steady-state regulation of the human DNA mismatch repair system. J Biol Chem 275:18424–18431PubMedCrossRef Chang DK, Ricciardiello L, Goel A et al (2000) Steady-state regulation of the human DNA mismatch repair system. J Biol Chem 275:18424–18431PubMedCrossRef
14.
Zurück zum Zitat Marra G, Iaccarino I, Lettieri T et al (1998) Mismatch repair deficiency associated with overexpression of the MSH3 gene. Proc Natl Acad Sci USA 95:8568–8573PubMedCrossRef Marra G, Iaccarino I, Lettieri T et al (1998) Mismatch repair deficiency associated with overexpression of the MSH3 gene. Proc Natl Acad Sci USA 95:8568–8573PubMedCrossRef
15.
Zurück zum Zitat Kariola R, Otway R, Lonnqvist KE et al (2003) Two mismatch repair gene mutations found in a colon cancer patient–which one is pathogenic? Hum Genet 112:105–109PubMed Kariola R, Otway R, Lonnqvist KE et al (2003) Two mismatch repair gene mutations found in a colon cancer patient–which one is pathogenic? Hum Genet 112:105–109PubMed
16.
Zurück zum Zitat Cannavo E, Marra G, Sabates-Bellver J et al (2005) Expression of the MutL homologue hMLH3 in human cells and its role in DNA mismatch repair. Cancer Res 65:10759–10766PubMedCrossRef Cannavo E, Marra G, Sabates-Bellver J et al (2005) Expression of the MutL homologue hMLH3 in human cells and its role in DNA mismatch repair. Cancer Res 65:10759–10766PubMedCrossRef
17.
Zurück zum Zitat Drummond JT, Genschel J, Wolf E et al (1997) DHFR/MSH3 amplification in methotrexate-resistant cells alters the hMutSalpha/hMutSbeta ratio and reduces the efficiency of base-base mismatch repair. Proc Natl Acad Sci USA 94:10144–10149PubMedCrossRef Drummond JT, Genschel J, Wolf E et al (1997) DHFR/MSH3 amplification in methotrexate-resistant cells alters the hMutSalpha/hMutSbeta ratio and reduces the efficiency of base-base mismatch repair. Proc Natl Acad Sci USA 94:10144–10149PubMedCrossRef
18.
Zurück zum Zitat Warren JJ, Pohlhaus TJ, Changela A et al (2007) Structure of the human MutSalpha DNA lesion recognition complex. Mol Cell 26:579–592PubMedCrossRef Warren JJ, Pohlhaus TJ, Changela A et al (2007) Structure of the human MutSalpha DNA lesion recognition complex. Mol Cell 26:579–592PubMedCrossRef
19.
Zurück zum Zitat Pinto C, Veiga I, Pinheiro M et al (2006) MSH6 germline mutations in early-onset colorectal cancer patients without family history of the disease. Br J Cancer 95:752–756PubMedCrossRef Pinto C, Veiga I, Pinheiro M et al (2006) MSH6 germline mutations in early-onset colorectal cancer patients without family history of the disease. Br J Cancer 95:752–756PubMedCrossRef
20.
Zurück zum Zitat Kloor M, Voigt AY, Schackert HK et al (2011) Analysis of EPCAM protein expression in diagnostics of Lynch syndrome. J Clin Oncol 29:223–227PubMedCrossRef Kloor M, Voigt AY, Schackert HK et al (2011) Analysis of EPCAM protein expression in diagnostics of Lynch syndrome. J Clin Oncol 29:223–227PubMedCrossRef
21.
Zurück zum Zitat Kansikas M, Kariola R, Nyström M (2011) Verification of the three-step model in assessing the pathogenicity of mismatch repair gene variants. Hum Mutat 32:107–115PubMedCrossRef Kansikas M, Kariola R, Nyström M (2011) Verification of the three-step model in assessing the pathogenicity of mismatch repair gene variants. Hum Mutat 32:107–115PubMedCrossRef
Metadaten
Titel
A putative Lynch syndrome family carrying MSH2 and MSH6 variants of uncertain significance—functional analysis reveals the pathogenic one
verfasst von
Jukka Kantelinen
Thomas v. O. Hansen
Minttu Kansikas
Lotte Nylandsted Krogh
Mari K. Korhonen
Saara Ollila
Minna Nyström
Anne-Marie Gerdes
Reetta Kariola
Publikationsdatum
01.09.2011
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 3/2011
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-011-9436-z

Weitere Artikel der Ausgabe 3/2011

Familial Cancer 3/2011 Zur Ausgabe

Introduction

Introduction

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.